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From a North American perspective, it is irresistible 
to extend cross-national comparisons from The 
Lancet Series on Health in Europe to include the USA, 
particularly in light of a 2013 US National Research 
Council and Institute of Medicine (NRC/IOM) report1 
showing that, for most health indicators and all ages 
to 75 years, the USA ranks worst or among the worst of 
17 similarly aﬄ  uent countries (including 15 in western 
Europe). The US health disadvantage was noted across 
diverse indicators including life expectancy (ﬁ gure); 
prematurity and low birthweight; infant, child, and 
maternal mortality; incidence of and mortality from 
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Although not the focus of the study, Talmud and 
colleagues9 show that even a diagnosis of a major 
mutation in familial hypercholesterolaemia does not 
always result in appropriate LDL-C treatment; the mean 
LDL-C concentration after treatment was only reduced by 
22%, to 5·49 mmol/L (recommended goal <2·6 mmol/L). 
Even in the mutation-negative cohort, with lower 
starting LDL-C concentrations, the mean post-treatment 
concentration was 4·22 mmol/L, a reduction of only 
28%. These results, from patients attending specialised 
lipid centres, are a cause for concern, especially as highly 
eﬀ ective statins that lower LDL-C in patients with familial 
hypercholesterolaemia by 50% are now generic and 
inexpensive. Randomised trials have shown that the more 
LDL-C is lowered, the lower the risk for coronary artery 
disease. Findings from Mendelian randomisation studies10 
show that polymorphisms associated with lower LDL-C 
starting presumably in childhood are associated with a 
far greater reduction in the risk of coronary heart disease 
than is reported in drug trials beginning later in life, after 
atherosclerosis has already developed.
Thus all people, irrespective of age, with raised LDL-C 
concentrations in whom no secondary cause can be 
identiﬁ ed, especially if they have a family history of 
premature coronary artery disease, should be treated for 
presumptive familial hypercholesterolaemia according 
to clinical criteria.5 To add the complexity of SNP analysis 
for minor genes and eliminate cascade LDL-C and clinical 
testing of relatives of patients with polygenic familial 
hypercholesterolaemia does not seem to be warranted, 
and could even be diversionary. 
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diabetes, cardiovascular disease, respiratory disease, 
infectious disease, and un inten tional and intentional 
injury; and disability. If the USA had been included in 
the Series, it would have ranked close to the eastern 
European countries on most indicators.2
The panel that undertook the NRC/IOM study1 
faced challenges shared by the authors of this Series, 
including a wide array of data for many indicators 
from many sources, data comparability limitations, 
lagged health eﬀ ects of upstream social policies, 
and diﬃ  culties in identifying discrete factors that 
contribute to cross-national health diﬀ erences when 
comparing economically, politically, and culturally 
distinct and evolving nations. The panel concluded 
that there were no simple explan ations and many 
factors were probably implicated.
An obvious diﬀ erence from western Europe is the 
absence of universal access to medical care in the USA. 
The fragmentation, specialist orientation, and primary 
care weakness noted in the Series by Bernd Rechel 
and colleagues3 as likely contributors to suboptimum 
health in the Commonwealth of Independent States 
may also have contributed to some poor US outcomes. 
Medical care deﬁ ciencies alone, however, cannot 
explain the pervasive US disadvantage across such 
disparate indicators. Obesity prevalence undoubtedly 
contributes to the high prevalence of, and mortality 
from, non-communicable diseases, but cannot 
explain high rates of HIV and sexually transmitted 
infections, adverse birth outcomes, gun violence, 
and overall injury incidence and mortality in the 
USA. Furthermore, studies have shown these health 
disadvantages even when examining only individuals 
of normal weight.4 The large ethnic and socioeconomic 
inequalities in health5 in the USA do not wholly 
explain the ﬁ ndings—disadvantages are evident when 
examining only white6 or aﬄ  uent populations.4,7,8
In the Series, Johan Mackenbach and colleagues9 con-
clude that the steadily increasing life expectancy in 
western Europe during the past four decades is a result 
of “combined eﬀ ects of economic growth, improved 
health care, and successful health policies (eg, tobacco 
control and road traﬃ  c safety)”. Although the USA and 
western Europe are not hugely dissimilar in terms of 
overall economic growth,10 the USA has higher rates of 
poverty, especially child poverty, lower social mobility,1 
and greater income inequality.11 Notwithstanding 
debates about causality,12 income inequal ity has been 
repeatedly and strongly linked with worse population 
health,13 and, along with poverty and low social 
mobility, might plausibly (through varied and complex 
pathways) be important in the US health disadvantage. 
The USA has been ahead of western Europe on 
tobacco control14,15 but probably not, at least recently, 
on transportation safety measures, and US rates of 
traﬃ  c deaths are substantially higher than are those in 
western Europe.1 The NRC/IOM panel recommended 
investigation of these potential explanations and other 
factors, including low participation in formal child care 
and preschool, weak social protections overall, and, 
perhaps more fundamentally as a driver of relevant 
policies and behaviours, a deeply rooted culture that 
values individualism more than social solidarity.
I hope the stark ﬁ ndings of the NRC/IOM report will 
prompt greater openness in the USA to approaches that 
have been associated with better results elsewhere. And 
as eastern and western European policy makers plan 
their health strategies in the face of severe economic 
constraints, let the shorter, sicker lives in the USA sound 
a cautionary note for those who would dismantle 
universal care systems and tear other holes in what 
appear, from this side of the Atlantic, to be precious 
social safety nets.
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Figure: Life expectancy at birth in Europe and the USA, 2009
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Why not send your best cardiology papers to The Lancet? 
The Lancet is planning a special issue to coincide with the 
European Society of Cardiology congress to be held from 
Aug 31–Sept 4, 2013, in Amsterdam, The Netherlands. 
We will consider high quality original research papers that 
will inﬂ uence clinical practice, and especially welcome 
reports that describe the results of randomised trials.
The deadline for regular submissions is May 27, 2013, 
via our online submission system. We will particularly 
welcome reports of clinical trials accepted for Hot Line 
sessions at the congress, for which the deadline for sub-
missions is Aug 1.
Please state in your covering letter that the submis-
sion is in response to this call for papers. If your work 
is being presented at the meeting and falls under 
an embargo policy, please tell us the date, time, and 
manner of presentation (poster or oral). If your paper is 
accepted here, publication on The Lancet’s website can 
be scheduled to coincide with the presentation.
Stuart Spencer
The Lancet, London NW1 7BY, UK
Cardiology: a call for papers
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